Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

547 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia.
Hoyt SB, Finocchio CJ, Croll E, Tawa GJ, Li H, Ma L, Li K, Liu L, Li R, Zhang X, Wilson K, Xu X, Shah P, Williams J, Fang Y, Bolanos LC, Gracia-Maldonado G, Kolt A, Robinson C, Free J, Edmondson EF, Difilippantonio S, Jones LM, Culver-Cochran AE, Rosenbaum JS, Starczynowski DT, Thomas CJ. Hoyt SB, et al. Among authors: thomas cj. ACS Med Chem Lett. 2024 Oct 23;15(11):1843-1851. doi: 10.1021/acsmedchemlett.4c00269. eCollection 2024 Nov 14. ACS Med Chem Lett. 2024. PMID: 39563805 Free PMC article.
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.
Jones LM, Melgar K, Bolanos L, Hueneman K, Walker MM, Jiang JK, Wilson KM, Zhang X, Shen J, Jiang F, Sutter P, Wang A, Xu X, Tawa GJ, Hoyt SB, Wunderlich M, O'Brien E, Perentesis JP, Starczynowski DT, Thomas CJ. Jones LM, et al. Among authors: thomas cj. J Clin Invest. 2020 Apr 1;130(4):2017-2023. doi: 10.1172/JCI127907. J Clin Invest. 2020. PMID: 32149729 Free PMC article.
Overcoming adaptive therapy resistance in AML by targeting immune response pathways.
Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, Abendroth J, O'Brien E, Hoyt SB, Berman E, Famulare CA, Mulloy JC, Levine RL, Perentesis JP, Thomas CJ, Starczynowski DT. Melgar K, et al. Among authors: thomas cj. Sci Transl Med. 2019 Sep 4;11(508):eaaw8828. doi: 10.1126/scitranslmed.aaw8828. Sci Transl Med. 2019. PMID: 31484791 Free PMC article.
Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.
Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, Cuzzola M, Maciejewski JP, Mulloy JC, Starczynowski DT. Rhyasen GW, et al. Cancer Cell. 2013 Jul 8;24(1):90-104. doi: 10.1016/j.ccr.2013.05.006. Cancer Cell. 2013. PMID: 23845443 Free PMC article.
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
Yohe ME, Gryder BE, Shern JF, Song YK, Chou HC, Sindiri S, Mendoza A, Patidar R, Zhang X, Guha R, Butcher D, Isanogle KA, Robinson CM, Luo X, Chen JQ, Walton A, Awasthi P, Edmondson EF, Difilippantonio S, Wei JS, Zhao K, Ferrer M, Thomas CJ, Khan J. Yohe ME, et al. Among authors: thomas cj. Sci Transl Med. 2018 Jul 4;10(448):eaan4470. doi: 10.1126/scitranslmed.aan4470. Sci Transl Med. 2018. PMID: 29973406 Free PMC article.
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the novel NAMPT Inhibitor OT-82.
Najera SS, Ricketts CJ, Schmidt LS, Medina JI, Saito K, Ileva L, Brender JR, James AM, Peer CJ, Gouker B, Karim BO, Chernova O, Wells C, Wei MH, Yang Y, Zhang X, Klumpp-Thomas C, Travers J, Chen L, Wilson KM, Issaq SH, Figg WD, Difilippantonio S, Kalen JD, Krishna MC, Thomas CJ, Ceribelli M, Heske CM, Crooks DR, Meier JL. Najera SS, et al. Among authors: thomas cj. Mol Cancer Ther. 2024 Oct 14. doi: 10.1158/1535-7163.MCT-24-0225. Online ahead of print. Mol Cancer Ther. 2024. PMID: 39397296
Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts.
Arakawa Y, Jo U, Kumar S, Sun NY, Elloumi F, Thomas A, Roper N, Varghese DG, Takebe N, Zhang X, Ceribelli M, Holland DO, Beck E, Itkin Z, McKnight C, Wilson KM, Travers J, Klumpp-Thomas C, Thomas CJ, Hoang CD, Hernandez JM, Del Rivero J, Pommier Y. Arakawa Y, et al. Among authors: thomas a, thomas cj. Cancer Res Commun. 2024 Mar 19;4(3):834-848. doi: 10.1158/2767-9764.CRC-24-0085. Cancer Res Commun. 2024. PMID: 38451783 Free PMC article.
Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma.
Kowalczyk JT, Wan X, Hernandez ER, Luo R, Lyons GC, Wilson KM, Gallardo DC, Isanogle KA, Robinson CM, Mendoza A, Heske CM, Chen JQ, Luo X, Kelly AE, Difilippantinio S, Robey RW, Thomas CJ, Sackett DL, Morrison DK, Randazzo PA, Jenkins LMM, Yohe ME. Kowalczyk JT, et al. Among authors: thomas cj. Mol Cancer Ther. 2021 Feb;20(2):307-319. doi: 10.1158/1535-7163.MCT-20-0525. Epub 2020 Nov 6. Mol Cancer Ther. 2021. PMID: 33158997 Free PMC article.
547 results